Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)Completed
NCT05104567Phase 2Updated Sep 24, 2025
Sponsor: Sanofi
Oesophageal Squamous Cell Carcinoma · Gastric Cancer · Hepatocellular Carcinoma · Colorectal Cancer
United States, Belgium, Chile, China, France +4 more
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid CancerCompleted
NCT00410761Phase 3Updated Sep 24, 2025
Sponsor: Genzyme, a Sanofi Company
Thyroid Cancer
United States, Australia, Austria, Belgium, Brazil +19 more
A Bioequivalence Study Comparing Two Different Strengths Formulations of Insulin Lispro in Patients With Type 1 DiabetesCompleted
NCT03903016Phase 1Updated Sep 24, 2025
Sponsor: Sanofi
Type 1 Diabetes
Germany
Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy ParticipantsCompleted
NCT04748926Phase 1Updated Sep 23, 2025
Sponsor: Principia Biopharma, a Sanofi Company
Healthy Volunteers
Australia
Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and OlderCompleted
NCT04498832Phase 3Updated Sep 23, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza Immunization · Healthy Volunteers
Japan
A Non-Interventional National Study in Pediatric Patients With Unexplained Enlarged SpleenCompleted
NCT04845958N/AUpdated Sep 23, 2025
Sponsor: Sanofi
Gaucher Disease, Splenomegaly · Acid SphingoMyelinase Deficiency
France
Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male SubjectsCompleted
NCT04171310Phase 1Updated Sep 23, 2025
Sponsor: Sanofi
Multiple Sclerosis
United Kingdom
A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19Completed
NCT04469621Phase 1Updated Sep 23, 2025
Sponsor: Sanofi
Corona Virus Infection
Argentina, Brazil, Chile, Mexico, Russia
Hydroxychloroquine in Outpatient Adults With COVID-19Terminated
NCT04333654Phase 1Updated Sep 23, 2025
Sponsor: Sanofi
Coronavirus Infection
United States, Belgium, France, Netherlands
Efficacy and Safety of Teicoplanin in CDADTerminated
NCT04003818Phase 4Updated Sep 23, 2025
Sponsor: Sanofi
Clostridium Difficile Infection-associated Diarrhea and Colitis
China
A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With PhenylketonuriaActive Not Recruiting
NCT05972629Phase 1, Phase 2Updated Sep 23, 2025
Sponsor: Sanofi
Phenylketonuria
United States, Argentina, Brazil, Israel, Turkey (Türkiye)
A Study of Isatuximab-based Therapy in Participants With LymphomaTerminated
NCT03769181Phase 1, Phase 2Updated Sep 23, 2025
Sponsor: Sanofi
Lymphoma
France, Italy, Netherlands, Portugal, South Korea +2 more
Pharmacokinetics of Amcenestrant in Female Hepatic Impaired Participants as Compared to Participants With Normal Hepatic FunctionTerminated
NCT05126329Phase 1Updated Sep 22, 2025
Sponsor: Sanofi
Hepatic Function Abnormal
Germany, South Korea
Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in ThailandCompleted
NCT04429295Phase 3Updated Sep 22, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Pertussis Immunisation · Diphtheria Immunisation · Polio Immunisation · Hepatitis B Immunisation
Thailand
A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)Completed
NCT04074187Phase 2, Phase 3Updated Sep 22, 2025
Sponsor: Sanofi
Thrombotic Thrombocytopenic Purpura
Japan
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)Terminated
NCT05061420Phase 2Updated Sep 22, 2025
Sponsor: Sanofi
Squamous Cell Carcinoma of Head and Neck
United States, Argentina, Canada, Chile, France +6 more
A Safety and Tolerability Study of BIVV020 in Adults With Cold Agglutinin DiseaseCompleted
NCT04269551Phase 1Updated Sep 22, 2025
Sponsor: Bioverativ, a Sanofi company
Autoimmune Haemolytic Anaemia
United States, Germany, Italy, Netherlands, Norway +1 more
A Study to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia Not Adequately Controlled on Statin TherapyCompleted
NCT04669041Phase 3Updated Sep 22, 2025
Sponsor: Sanofi
Hypercholesterolemia
China
Developing a Management Approach for Patients With "Late-Onset" Pompe DiseaseActive Not Recruiting
NCT03694561N/AUpdated Sep 22, 2025
Sponsor: Duke University
Pompe Disease · Pompe Disease (Late-onset) · GAA Deficiency
United States
Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in AdultsCompleted
NCT04142086Phase 1Updated Sep 22, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Yellow Fever (Healthy Volunteers)
United States
A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension PeriodCompleted
NCT05002933Phase 4Updated Sep 22, 2025
Sponsor: Sanofi
Type 2 Diabetes Mellitus
China
Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic DrugsCompleted
NCT04980027Phase 4Updated Sep 22, 2025
Sponsor: Sanofi
Type 2 Diabetes Mellitus
India
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma PatientsCompleted
NCT05087212Phase 4Updated Sep 22, 2025
Sponsor: Sanofi
Autologous Haematopoietic Stem Cell Transplant
China
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in InfancyCompleted
NCT05929651Phase 4Updated Sep 22, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningococcal Immunisation · Healthy Volunteers
Argentina
First-in-human Study to Assess Safety and Tolerability of a Single Subcutaneous Dose of SAR441255 in Lean to Overweight SubjectsCompleted
NCT04521738Phase 1Updated Sep 22, 2025
Sponsor: Sanofi
Overweight · Healthy Subjects
United States

Previous page Next page